



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Telix Pharmaceuticals Appoints Dr. David Cade as Chief Business Officer and Head of Investor Relations

Melbourne (Australia) – 7 October 2019. Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on “molecularly-targeted radiation” (MTR), has today announced that Dr. David Cade has joined the Telix executive leadership team in the role of Chief Business Officer and Head of Investor Relations.

David brings over 20 years of significant commercial, clinical and public company experience to Telix. Notable prior executive roles include Chief Medical Officer at Cochlear and Sirtex, where his responsibilities included not only clinical strategy but also commercial and investor-facing aspects. David’s qualifications include a Bachelor of Medicine / Bachelor of Surgery (MBBS) from Monash University and a Master of Business Administration (MBA) from the University of Melbourne with finance studies at ESADE Business School. David is a graduate of the Australian Institute of Company Directors.

Telix CEO Dr. Christian Behrenbruch stated, “In the period since our IPO we have assembled a highly capable executive team to deliver to shareholders the exciting potential of Telix’s oncology pipeline while systematically addressing founder/key person risk. I’m pleased to welcome David to the team as we prepare for market launch of our first products and face a significant deal flow of partnership opportunities. David’s multi-faceted skillset and detailed understanding of the radiopharmaceutical space is of real benefit to Telix.”

Dr. Cade added, “Telix is a rare example of an Australian biopharmaceutical company that has the potential to rapidly become a global category leader. Telix is an exciting company built on the expertise in radiopharmaceuticals that exists in Australia and in a limited number of industry clusters around the globe. The Company has made an enormous amount of progress in a relatively short duration. I am delighted to be joining Chris and the team at a time when Telix is undergoing rapid growth and transformation into a commercial-stage company.”

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Lisa Wilson
In-Site Communications
Tel: +1 212 452 2793
Email: lwilson@insitecony.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.